NASDAQ · Drug Manufacturers - Specialty & Generic · USD
Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis
Indivior Pharmaceuticals, Inc. (INDV) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
INDV Key Statistics
As of Oct 21, 2026Trading
- Open
- $34.92
- Previous Close
- $34.77
- Day's Range
- 34.56–35.15
- 52-Week Range
- 24.03–42.81
- Volume
- 3.24M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.18
Valuation
- Market Cap
- $4.11B
- P/E Ratio
- 12.47
- Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
- 7.12
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 3.09
- EPS (ttm)Profit attributable to each share over the last twelve months.
- 2.79
Financials (FY)
- Revenue (FY)
- $1.24B+4.29%
- Net Income (FY)
- $210.00M+2,900.00%
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 26.75%
- Shares Outstanding
- 118.03M
- 1-Year Return
- +44.42%
Dividend and dates
- Ex-Dividend Date
- October 30, 2026
- Earnings Date
- October 29, 2026
- Avg Volume
- 2.30M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, INDV closed at $34.79, +44.42% over 1 year.
Indivior Pharmaceuticals, Inc. (INDV) has a market capitalization of $4.11B.
In fiscal 2025, INDV reported revenue of $1.24B.
INDV Stock Return by Calendar Year
Indivior Pharmaceuticals, Inc. (INDV) 10-year return: what $10,000 became
- 1 year
- $10,000 $14,442
- +44.42%
- 5 years
- $10,000 $22,089
- +120.89%
- 10 years
- $10,000 $18,262
- +82.62%
If you had invested $10,000 in Indivior Pharmaceuticals, Inc. (INDV) 10 years ago, at the close on October 21, 2016, it would have been worth $18,262 at the close on October 21, 2026: +82.62% in total, +6.21% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −3.04% |
| 2025 | +188.66% |
| 2024 | −18.60% |
| 2023 | −29.79% |
| 2022 | +26.09% |
| 2021 | +135.49% |
| 2020 | +181.73% |
| 2019 | −61.48% |
| 2018 | −75.45% |
| 2017 | +54.90% |
| 2016 (partial year) | −5.59% |
As of October 21, 2026.
INDV Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $1.24B | $210.00M | 16.9% |
| 2024 | $1.19B | $7.00M | 0.6% |
| 2023 | $1.09B | −$126.00M | −11.5% |
| 2022 | $901.00M | −$44.00M | −4.9% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $1.24B | $993.00M | $265.00M | $210.00M | 16.9% |
| 2024 | $1.19B | $957.00M | $234.00M | $7.00M | 0.6% |
| 2023 | $1.09B | $919.00M | $247.00M | −$126.00M | −11.5% |
| 2022 | $901.00M | $750.00M | $215.00M | −$44.00M | −4.9% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
INDV Valuation vs Drug Manufacturers - Specialty & Generic Median
Median of 97 stocks| Metric | INDV | Drug Manufacturers - Specialty & Generic median | vs median |
|---|---|---|---|
| P/E | 12.47 | 20.31 | 39% below |
| P/S ratio | 3.09 | 2.10 | 47% above |
| Profit margin | 26.75% | −8.14% | 34.9 pts above |
Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
Indivior to Report Third Quarter 2026 Financial Results
YahooIndivior: Sublocade Growth And Improving Profitability Create Upside Potential
SeekingAlphaIndivior Pharmaceuticals, Inc. Declares Special Cash Dividend
YahooIndivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?
YahooIndivior Pharmaceuticals Inc. (INDV) Loses 12.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
YahooIndivior Q2 2026 Earnings Call: Complete Transcript
Benzinga
All 15 articles ↓Show fewer ↑
Barclays Maintains Overweight on Indivior Pharmaceuticals, Lowers Price Target to $43
BenzingaINDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
YahooSupernus And Indivior Merger: There May Be Some Skepticism, But I Have Faith In This Deal
SeekingAlphaIndivior Q2 Earnings Call Highlights
MarketBeatIndivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimates
YahooSupernus Pharmaceuticals, Indivior Pharmaceuticals to Merge in All-Stock Deal
YahooSupernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue
BenzingaIndivior Pharmaceuticals Raises FY2026 Sales Guidance from $1.215B-$1.285B to $1.295B-$1.365B vs $1.245B Est
BenzingaSupernus Pharmaceuticals To Merge With Indivior Pharmaceuticals; SUPN Stockholders Will Receive 1.5401 Shares Of INDV Per SUPN Share; Indivior Stockholders Will Receive One-Time Special Cash Dividend Of $1B Immediately Prior To Closing; Expected To Generate $125M In Annual Cost Synergies
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Drug Manufacturers - Specialty & Generic Stocks
Takeda Pharmaceutical Company Limited
$63.67B
TEVATeva Pharmaceutical Industries Limited
$47.37B
HLNHaleon plc
$44.06B
ZTSZoetis Inc.
$32.90B
UTHRUnited Therapeutics Corporation
$24.17B
VTRSViatris Inc.
$21.19B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B